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INTRODUCTION
Cyclosporine (CsA) was first approved by the US Food
and Drug Administration in the early 1980s for pro-
phylactic anti-rejection therapy in patients receiving
allogeneic transplants (kidney, liver, and heart). Its
introduction has significantly improved both allograft
and patient survival for over two decades [1,2]. 
The immunosuppressive action of CsA involves the
intracellular interaction of CsA and calcineurin pho-
sphatase, which reduces the production of interleukin-2
(IL-2). CsA initially binds to a specific family of receptors
known as cyclophilins [3]. This drug-receptor complex
inhibits the activation of calcineurin phosphatase, a
secondary messenger in the dephosphorylation and
activation of the nuclear factor of activation of T-cells
(NF-AT). NF-AT is a regulatory protein that promotes the
transcription and production of IL-2 and other cytokines
that promote the growth and proliferation of T- and B-
cells [4]. Inhibition of IL-2 production by CsA halts the
proliferation and activation of helper and cytotoxic T-cells
[5]. 
Despite the therapeutic benefits of CsA, several adverse
effects have been reported in both transplant and non-
transplant settings (i.e., autoimmune disorders), including
toxicities (nephrotoxicity, hepatotoxicity, and neuro-
toxicity), hypertension, dyslipidemia, gingival hyperplasia,
hypertrichosis, malignancies, and an increased risk of
cardiovascular events [2,6]. The most clinically important
complication is chronic CsA nephropathy, which is one of
the known non-immunological factors causing chronic
allograft nephropathy [7]. Chronic CsA nephropathy is
characterized by progressive renal dysfunction, afferent
arteriolopathy, inflammatory cell influx, striped tubuloin-
terstitial fibrosis, and increased intrarenal immunogenicity
[8-10]. Nankivell et al. [11] showed that almost all recipients
presented evidence of chronic CsA nephropathy after 10
years of treatment with calcineurin inhibitors. The exact
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REVIEWmechanism of this complication is not fully understood,
although many potential mechanisms have been
proposed. 
Using a well-established animal model, we and other
groups recently demonstrated that the mechanism of
CsA-induced renal injury includes immunological and
non-immunological pathways, as outlined in Figure 1.
This review article summarizes our current understanding
of the pathogenesis of chronic CsA nephropathy and
discusses recent literature on the prevention and delay of
this complication. 
PREVIOUSLY ESTABLISHED MECHANISMS
OF CsA-INDUCED RENAL INJURY
CsA-induced low-grade ischemia
Long-term administration of CsA rapidly decreases
glomerular filtration rate (GFR) and renal blood flow by
inducing vasoconstriction or increased intrarenal vascular
resistance, which ultimately results in low-grade ischemic
injury [2,6]. Chronic ischemia caused by CsA is believed to
be associated with reactive oxygen species and lipid
peroxidation [12,13]. This hypothesis is supported by the
observation that antioxidant therapies significantly
attenuate chronic CsA nephropathy [14,15]. 
The mechanism responsible for vasoconstriction is
partially related to the activation of the intrarenal renin-
angiotensin system (RAS) and imbalances in prostaglandins
and thromboxane [13,16,17]. In addition, hypersecretion
of endothelin-1 plays an important role in CsA-induced
vasoconstriction [18]. Endothelin-1 is a potent vasocon-
strictor, widely released in the kidney and vascular beds,
and acts locally to increase vascular tone and regulate
blood flow, GFR, and sodium reabsorption. Furthermore,
endothelin-1 can also disrupt renal architecture through
its effects on extracellular matrix (ECM) accumulation
and tubulointerstitial fibrosis. However, after long-term
withdrawal of CsA, both vasoconstriction and afferent
arteriolopathy are shown to be normalize. CsA may also
increase systemic vascular resistance associated with
activation of the sympathetic nervous system [19].
CsA-induced activation of the renin-angiotensin
system
Activation of the RAS, especially the intrarenal RAS,
plays an essential role in the pathogenesis of chronic
CsA nephropathy [20,21]. However, the mechanism of
RAS activation in this complication remains unknown.
One accepted hypothesis is that CsA increases renin
release from juxtaglomerular cells. In a reproducible rat
model of chronic CsA nephropathy developed by Rosen
et al. [22] and Elzinga et al. [23], CsA administration to
animals on a low-salt diet induced a significant decrease
in GFR and histological changes similar to those described
in patients undergoing long-term CsA therapy. Salt deple-
tion activates the RAS, which is implicated in the changes
in renal hemodynamics and function that follow CsA
administration. Using this model, we and other groups
clearly demonstrated that CsA significantly increases
renin and angiotensin II (Ang II) immunoreactivity in
the kidney [21,24,25], supporting a role for the intrarenal
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Figure 1. A schematic diagram of the
pathogenesis of chronic CsA-induced renal
injury. Chronic treatment with CsA induces
renal injury by immunologic and non-
immunologic pathways. The non-immunologic
pathway includes hemodynamic (low-grade
ischemia) and non-hemodynamic (mediators)
mechanisms, although both ultimately result
in tubulointerstitial inflammation, striped
fibrosis, and an increased rate of chronic
rejection. The immunologic pathway may be
triggered by the endogenous production of
HSP 70, a known activator of TLRs. Con-
sequently, activation of the innate immune
system by TLRs and MHC class II molecules
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RAS in the pathogenesis of chronic CsA nephropathy. 
Activation of the intrarenal RAS induces renal injury
via hemodynamic and non-hemodynamic pathways.
The RAS mediates vasoconstriction hemodynamically
and thus leads to low-grade ischemia, as reviewed above.
However, the RAS may also induce renal injury non-
hemodynamically via stimulation of tubulointerstitial
inflammation, the expression of transforming growth
factor-beta 1 (TGF-β1) and vascular endothelial growth
factor (VEGF), and increased renal cell apoptosis [26-29].
Blocking this system with either angiotensin-converting
enzyme (ACE) inhibitors or angiotensin II (Ang II)
receptor type I antagonists mitigates all of the above
parameters and confers a renoprotective effect during
chronic CsA nephropathy [21,25-28]. 
The pathogenesis of chronic CsA nephropathy may
involve an association between the RAS and expression
of the Klotho gene. The Klotho gene is an anti-aging gene
involved in the suppression of several aging phenotypes
[30]. Klotho gene expression in the kidneys is greatly
reduced in patients with chronic renal failure [31] and
is also suppressed in acute renal failure in ischemic-
reperfusion injury murine models [32]. Recently, we found
that the activation of the RAS suppresses Klotho gene
expression in an animal model of CsA nephropathy
and that blocking the RAS with Ang II receptor type 1
antagonists alleviates suppression of the Klotho gene and
tissue injury (unpublished data). These results suggest
that RAS activation suppresses Klotho gene expression
and leads to chronic CsA-induced renal injury. 
Nitric oxide and CsA-induced renal injury
In the kidney, nitric oxide (NO) is a vasodilating factor
that plays a key role in maintaining vascular tone. In addi-
tion, NO decreases glomerular thrombosis and ischemia,
mesangial cell proliferation, ECM protein synthesis, and
interstitial inflammatory cell infiltration. 
NO is produced from L-arginine by the action of NO
synthase (NOS), of which at least three isoforms have
been identified: neuronal NOS (nNOS), inducible NOS
(iNOS), and endothelial NOS (eNOS). These three NOS
isoforms are all found in the kidney: nNOS is specifically
expressed in macula densa cells, iNOS has been observed
in mesangial and proximal tubular cells, and eNOS is
expressed mainly in endothelial cells of the afferent and
efferent arterioles and glomerular capillaries [33]. Chronic
CsA treatment has been shown to differentially influence
NOS isoform expression and interfere with NO production;
however, contradictory results have also been reported
[34-37]. 
The role of NO in the pathogenesis of chronic CsA
nephropathy has been examined. We demonstrated that
exogenous supplementation with L-arginine effectively
prevents CsA-induced renal dysfunction, arteriolopathy,
and interstitial fibrosis in rats [38]. Shihab et al. [39,40]
also reported that L-arginine treatment attenuates CsA-
induced TGF-β1 over-expression and ECM deposition,
whereas these effects are reversed by treatment with N-
nitro-L-arginine, a potent competitive inhibitor of NO
biosynthesis.
Osteopontin as a pro-inflammatory cytokine in
CsA-induced renal injury
The molecular mechanism underlying chronic CsA
nephropathy is multifactorial. Because interstitial
inflammatory events precede ongoing fibrosis [9], the
up-regulation of chemoattractants and subsequent
inflammatory cell infiltration are thought to play impor-
tant roles in this condition. 
Osteopontin (OPN) is a highly acidic phosphoprotein
containing an arginine-glycine-aspartic acid (RGD)
motif. It is involved in cell adhesion and migration [41]
and is expressed by several cell types in a constitutive
or inducible fashion. These include osteoclasts, some
epithelial cells, macrophages, T-cells, smooth muscle
cells, and tumor cells [42-47]. OPN acts as a chemotactic
factor for macrophages and monocytes by binding to
ligands such as αvβ3 integrin, CD44, collagen type I, and
fibronectin [48,49]. The functional role of OPN, with
respect to macrophage attraction, has been recently
described in vivo and in vitro [41,50]. Moreover, the
subcutaneous injection of OPN into rats produces massive
macrophage accumulation, which is inhibited by the
administration of an anti-OPN antibody [51]. 
In the kidney, OPN is expressed constitutively in the
renal medulla in the loop of Henle and the distal con-
voluted tubules; it is absent in the normal renal cortex,
with the exception of the parietal epithelium of Bowman’s
capsule. The up-regulation of OPN expression is strongly
correlated with macrophage infiltration in several models
of kidney diseases [28,52-55]. Young et al. [9] and Pichler
et al. [28] reported that CsA treatment up-regulates
OPN gene expression and is correlated with interstitial
macrophage infiltration and fibrosis. We found that OPN
mRNA and protein were constitutively present in the
tubular epithelium, collecting ducts, and uroepithelial cells
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were negative for OPN. In contrast, the levels of OPN
mRNA and protein increased dramatically in the tubular
epithelium and Bowman’s capsule cells in CsA-treated rat
kidneys. The most striking change was observed in the
renal cortex, which normally expresses very little con-
stitutive OPN. Of note, the sites of strong OPN expression
were in areas of macrophage influx and severe tubuloin-
terstitial fibrosis [25,56]. Furthermore, a study in OPN-
null mice demonstrated that the lack of OPN expression
attenuated chronic CsA nephropathy [57]. These findings
imply that OPN plays a pathogenic role in CsA-induced
renal injury.
TGF-β β1 as a pro-fibrotic cytokine in CsA-induced
renal injury
TGF-β1 is a key cytokine implicated in the pathogene-
sis of a wide range of kidney diseases characterized by
glomerulosclerosis and tubulointerstitial fibrosis, including
chronic CsA nephropathy. Both in vivo and in vitro
studies have shown that CsA administration is associated
with dose-dependent increases in TGF-β1 expression.
Shihab et al. [58,59] demonstrated that CsA-induced
TGF-β1 up-regulation results in tubulointerstitial fibrosis,
probably via its actions on ECM synthesis and degradation,
and plasminogen activator inhibitor-1 plays a role in this
process. Furthermore, administration of a specific TGF-β-
neutralizing antibody ameliorated morphological
alterations and preserved renal function in a mouse model
of chronic CsA nephropathy [60]. 
TGF-β1 is secreted as a biologically inactive complex
requiring in vivo activation. This latent TGF-β1 complex is
activated via cleavage of its N-terminal latency-associated
peptide to yield mature dimeric TGF-β1 through enzymatic
and non-enzymatic mechanisms, or by the presence of the
proteoglycan decorin and the scavenging protein α2-
macroglobulin [61-65]. Therefore, increased amounts of
TGF-β1 mRNA or protein may not actually represent
parallel changes in its biologic activity. 
Keratoepithelin (βig-h3) is a secreted matrix protein
originally identified from a TGF-β1-stimulated human
lung adenocarcinoma cell line (A549) [66]. βig-h3 has
been proposed as one of the ECM components [67];
although the precise physiologic function of βig-h3 is
unclear, it may connect various matrix components and
resident cells, thereby serving as a bifunctional linker
protein [68,69]. Thus, βig-h3 expression has been used
to assess the biological activity of TGF-β1 [70]. Langham
et al. [71] reported that βig-h3 production increased
significantly in non-renal transplant recipients with
chronic CsA nephropathy. More recently, we found that
βig-h3 mRNA and protein were normally expressed in the
cortex and outer medulla, specifically localized in the
terminal portion of afferent arterioles (vascular pole of
glomerulus), the S3 segment (parser recta) of the proximal
tubules, and the distal convoluted tubules. However, in
the CsA-treated rat kidney, βig-h3 gene expression was
significantly up-regulated in the interstitium, but not in
afferent arterioles or tubules, where interstitial expansion
and fibrosis developed [72]. Thus, βig-h3 may be a useful
index of TGF-β1 bioactivity and may reflect the degree of
tubulointerstitial injury in chronic CsA nephropathy.
CsA-induced cell death
Tubulointerstitial injury is the prominent feature of
chronic CsA nephropathy, and the major form of cell death
is apoptosis [73]. Excessive loss of cellularity via apoptosis
has been observed in fibrotic areas in renal biopsy speci-
mens obtained from patients receiving long-term CsA
therapy [74]. Apoptosis is an active mechanism of cell
clearance and plays a key role in the regulation of cell
number during development, in tissue homeostasis, and
following insults. In the kidney, apoptosis may be
beneficial [75] but is deleterious if enough resident cells
are lost [76]. 
CsA has been shown to induce apoptotic cell death
not only in T-lymphocytes, thus interfering with T-cell
function [77], but also in some renal cells, resulting in
the deterioration of kidney structure [26,78,79]. Thomas
et al. [26]  were the first to characterize the close link
between apoptosis and interstitial fibrosis in a rat model
of chronic CsA nephropathy. Subsequently, we and other
groups have reported that CsA-induced renal cell apoptosis
is associated with gene families such as the Bcl-2 proteins,
Fas and Fas-ligand, p53, and the caspases [73,80], and
that Ang II, NO, intrarenal growth factors (TGF-β1),
epidermal growth factor (EGF), and macrophages are
also involved [21,26,81-83]. 
CsA-induced activation of nuclear factor-kappa B
and activating protein-1
Transcription factors such as nuclear factor-kappa B
(NF-κB) and activating protein-1 (AP-1) regulate the gene
expression of several cytokines, chemotactic proteins,
adhesion molecules, and matrix proteins involved in
inflammation, immunologic responses, cell differentiation,
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and the control of growth [84]. The transcription factors
NF-κB and AP-1 are activated by a number of physiological
and non-physiological stimuli such as cytokines, mitogens,
viruses, mechanical factors, oxidative stress, and a variety
of chemical agents [85-87]. Recent studies suggest that
the activation of NF-κB and AP-1 is involved in the tran-
scription of monocyte chemoattractant protein-1 and
TGF-β1 in the kidney, which is regulated by Ang II or
proteinuria [84,88-90]. In rats, Asai et al. [91] reported
that the administration of CsA stimulated NF-κB and
AP-1 DNA-binding activity, and this effect was blocked
by the ACE inhibitor benazepril and by magnesium sup-
plementation. In addition, we reported the involvement of
the activation of NF-κB and AP-1 during the activation of
innate immunity in chronic CsA nephropathy (described
below) [92].
NEWLY DESCRIBED MECHANISMS OF
CSA-INDUCED RENAL INJURY
Toll-like receptors and inflammation
The innate immune system primarily evolved as a rapid
first line of defense, and is initiated by stimulation of toll-
like receptors (TLRs) via their specific ligands [93,94].
Growing evidence indicates that the TLRs play a potential
role in the pathophysiology of injury-associated kidney
diseases [95]. Previously, we reported that CsA-induced
renal injury produces endogenous TLR ligands such as
heat shock protein (HSP) 70, up-regulates major histo-
compatibility complex (MHC) class II protein and TLR
expression in renal tubular cells, and promotes the matu-
ration of dendritic cells [92]. HSP 70 is an activator of TLRs
and the innate immune system, and TLRs are recognized
as sensors of pathogen-associated molecular patterns
crucial for the initiation of an innate immune response
[96,97]. Recently, we demonstrated that macrophage
depletion decreased both TLR2 and MHC class II
expression in renal tubular cells [83], which suggests a
role for macrophages in immunologic injury. These results
suggest the close association between the activation of
innate immunity and chronic CsA-induced renal injury.
CsA-mediated impairment of urine concentration
CsA causes tubular dysfunction characterized by
polyuria, calcium wasting, distal tubular acidosis, and
hyperkalemia. Of these, impaired urine concentration is a
predominant feature of chronic CsA nephrotoxicity [9],
but the molecular mechanisms underlying this issue
remain unknown.
In general, the urine-concentrating process is controlled
by the aquaporin (AQP) system and the urea transporters
(UTs) [98,99]. AQPs are a family of membrane proteins
that play an important role in the reabsorption of water in
the kidney. To date, at least 11 different types of AQPs
have been cloned [98,100]. AQP1 aids in the rapid
reabsorption of large quantities (70-80%) of filtered
water and is constitutively present on both the apical
and basolateral membranes of epithelial cells in the
proximal tubule and the descending thin limbs of
Henle’s loop, and in endothelial cells of the descending
vasa recta [101]. AQPs 2-4 are involved in the movement
of water across the apical membrane in collecting duct
principal cells and are localized to the basolateral
membrane of this cell type. Reabsorbed free water
determines the osmolality of the final voided urine, and
this AQP-related process is controlled by vasopressin
[98]. The UT family includes renal UT (UT-A) and the
erythrocyte urea transporter (UT-B) [102]. In the kidney,
UT-A1 and UT-A3 are responsible for the accumulation of
urea in the inner medulla, and they are present in the
inner medullary collecting duct. UT-A2 is present in the
descending thin limbs of Henle’s loop, and UT-B in the
descending vasa recta [103-106]. We have demonstrated
that chronic CsA treatment decreases AQP 1-4 and UT
(UT-A2, UT-A3, and UT-B) production in rat kidneys,
which may account for the impairment of urinary concen-
trating ability (polyuria, increased fractional excretion of
sodium, and decreased free-water reabsorption) [107].
Recently, down-regulation of tonicity-responsive enhancer
binding protein (TonEBP) has been proposed as a mediator
of decreased AQP and UT transcription [108]. TonEBP is
inhibited in the renal medulla secondary to reduced
medullary tonicity, which is in turn the result of the down
regulation of renal sodium transporters.
CsA-induced urinary calcium wasting
Another manifestation of renal tubular dysfunction
caused by CsA is calcium wasting associated with the
dysregulation of parathyroid hormone, which ultimately
results in high bone turnover (osteopenia). Most of the
filtered calcium (approximately 60%) is reabsorbed in
the proximal tubule, and the remainder is reabsorbed in
the medullary thick ascending limb of Henle’s loop, the
distal convoluted tubule, and the connecting segment
[109]. The calcium binding protein calbindin plays an
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subclasses of this protein with relative molecular masses
of 9,000 and 28,000 Da have been recognized. Calbindin
D9k is present in high concentrations in the proximal small
intestine and facilitates intestinal calcium absorption
[111]. Calbindin28k is expressed in the distal nephron
segments of the rat kidney and is assumed to take part
in calcium reabsorption [112]. Recent experimental
studies by our laboratory [113] and by Steiner et al. [114]
have demonstrated that chronic CsA treatment reduces
calbindin28k immunoreactivity in the distal nephron, and
this is accompanied by a significant decrease in serum
calcium concentration and an increase in urinary calcium
excretion. These results suggest that CsA-mediated
suppression of calbindin28k production is a critical factor
in renal calcium wasting.
Endoplasmic reticulum stress and autophagy
The endoplasmic reticulum (ER) has evolved a highly
specific signaling pathway called the “unfolded protein
response,” a protective mechanism that reduces protein
load and increases nascent protein folding, thus con-
tributing to cell protection [115]. However, when ER stress
is excessive and/or prolonged, the initiation of apoptosis
is promoted [116,117]. Recently, Pallet et al. [118] demon-
strated that CsA induces ER stress in renal tubular cells,
which then activates autophagy as a protection against cell
death [119]. Autophagy is a protective mechanism against
various cellular stresses, including nutrient deprivation,
hypoxia, and growth factor deprivation, and promotes cell
survival. Recent evidence suggests that ER stress drives
autophagy [120-122] and that autophagy alleviates ER
stress and reduces cell death. We have demonstrated that
prolonged ER stress induces apoptosis in an animal
model of chronic CsA nephropathy [123]. Short-term
treatment of CsA activated both the ER stress and pro-
apoptotic responses, whereas long-term treatment of CsA
decreased the ER stress response and increased the pro-
apoptotic response. These results suggest that an imbal-
ance between the two responses may cause apoptosis by
depleting molecular chaperones and activating the pro-
apoptotic pathway in chronic CsA-induced renal injury. 
STRATEGIES TO PREVENT OR REDUCE
CHRONIC CsA NEPHROPATHY
Reduction or withdrawal of CsA
Whether chronic CsA nephropathy is reversible is
controversial. Traditionally, acute CsA nephropathy has
been regarded as reversible after CsA dose reduction or
complete withdrawal. However, chronic CsA-induced
tubulointerstitial injury is considered to be persistent and,
in some cases, progressive. 
Weir et al. [124]  investigated the long-term effects of
the reduction or withdrawal of calcineurin inhibitors in a
cohort of renal transplant recipients. After reduction or
complete cessation of calcineurin inhibitors, a significant
improvement in renal function was observed. Although
an improvement in renal function was not recorded in
all patients, this strategy was beneficial in most patients
and reduced the rate of allograft loss in patients with
nephrotoxicity. In low-salt diet-fed rats, Elzinga et al. [23]
reported a progressive improvement in the GFR at 4
weeks after CsA discontinuation, but cortical fibrosis and
tubular atrophy were unchanged. Using the same model,
Franceschini et al. [125] carried out a long-term study in
which the rats were administered CsA for 5 weeks,
followed by the discontinuation of CsA for 2 or 8 weeks.
The authors demonstrated that the degree of renal function
and arteriolopathy was similar to that in placebo-treated
controls after 8 weeks of CsA withdrawal, but tubuloin-
terstitial fibrosis was not reversed. Therefore, there is
dissociation between GFR and tissue injury in this animal
model, and the low-salt diet is suggested to be an impor-
tant factor. 
To clarify the molecular mechanism of irreversible
damage in chronic CsA nephropathy, we carried out two
prolonged studies using two dosages of CsA (7.5 and 15
mg/kg) and multiple periods of drug washout [126].
Surprisingly, both renal function and morphological
alterations (tubulointerstitial fibrosis and arteriolopathy)
were reversed in rats with both dosages of CsA at 5 weeks
after withdrawal, and the alleviation of tubulointerstitial
fibrosis was observed after 10 weeks. At the molecular
level, the reversibility of chronic CsA nephrotoxicity was
closely associated with the down-regulation of OPN and
TGF-β1 gene expression, the up-regulation of EGF
production, and a decrease in renal cell apoptosis [82].
These conflicting results between our studies and previous
reports lead us to speculate that the effect of CsA with-
drawal in chronic CsA-induced renal injury may depend
on the CsA dosage or on the timing of drug elimination. 
Given the recently demonstrated association between
prolonged ER stress and apoptosis [123], kidney allografts
may well adapt to CsA-induced ER stress by inducing the
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expression of molecular chaperones. The duration and
intensity of CsA-induced ER stress may provide a rationale
for the reduction or withdrawal of CsA to prevent chronic
CsA nephropathy. In addition, because the activation of
autophagy indicates that cellular stress has occurred, the
early detection of autophagy may facilitate the timely
reduction or withdrawal of CsA treatment [119]. Clinical
trials are needed to clarify these issues.
Pharmacologic intervention
Chronic CsA nephropathy is a major problem in trans-
plant recipients and patients with autoimmune disorders,
as it may lead to end-stage renal disease requiring dialysis.
Therefore, renal function should always be carefully moni-
tored, even in patients in whom renal function appears
to be stable. In addition, early recognition and pharmaco-
logical intervention may be necessary to minimize the rate
of allograft loss or chronic renal failure.
It is generally accepted that the modulation of vasoactive
factors (Ang II and NO) effectively prevents CsA-induced
renal injury. Previous studies clearly demonstrated that
the concomitant administration of ACE inhibitors and
Ang II type I receptor antagonists significantly reduced
arteriolopathy, interstitial fibrosis, and tubular atrophy,
independently of hemodynamic effects. However, renal
dysfunction was not attenuated, and a potential expla-
nation for this discrepancy has been discussed above. The
molecular mechanisms underlying the renoprotective
effects of these drugs in chronic CsA nephropathy may
be related to their actions on inflammatory mediators,
pro-fibrotic cytokines,  matrix proteins, apoptotic cell
death, and innate immunity [9,16,21,26-28,127). BQ123,
an endothelin receptor blocker, partially improved renal
function, but did not reduce structural damage [128].
Similarly, exogenous supplementation of L-arginine, a
substrate for NO synthase, also conferred a renoprotective
effect [38,40]. This effect was associated with the reduc-
tion of VEGF expression and the increased availability of
NO.
Drugs with anti-fibrotic properties such as the TGF-β
antibody [60], statins [129], pirfenidone [59,130], and
hepatocyte growth factor [131] have been shown to have
renoprotective effects in chronic CsA nephropathy. Statins
are competitive inhibitors of 3-hydroxy-3-methylglutaryl-
coenzyme A (HMG-CoA) reductase, the key enzyme that
regulates the synthesis of cholesterol from mevalonic
acid by suppressing the conversion of HMG-CoA [132].
The inhibition of HMG-CoA reductase by statins has
pleiotropic effects independent of their lipid-lowering
effects (e.g., anti-inflammatory and anti-arteriosclerotic
effects) [133,134]. These benefits are mirrored in many
renal disease models [135-138]. In a rat model of chronic
CsA nephropathy, we showed that pravastatin treatment
attenuated interstitial inflammation and fibrosis. The
suppression of OPN, TGF-β1, and intrarenal C-reactive
protein expression along with increased eNOS expression
may be responsible for the renoprotective properties of
pravastatin [129].
Anti-inflammatory drugs, such as pentosan polysulfate
[139] and mycophenolate mofetil (MMF) [25], are also
suggested to have protective effects in chronic CsA-
induced renal injury. In a study by Schwedler et al. [139],
pentosan polysulfate reduced tissue injury but was
unable to improve renal function. We have reported that
the administration of MMF is partially effective in
preventing the development of chronic CsA nephropathy.
Moreover, the combination of MMF and losartan (an Ang
II type 1 receptor antagonist) or the administration of
MMF after CsA withdrawal affords superior protection
compared to losartan monotherapy [25] or CsA withdrawal
alone [140]. 
Other strategies include vitamin E [14], recombinant
human erythropoietin (rHuEPO) [141], rosiglitazone
[142,143], or spironolactone [144,145] therapy. Vitamin E
treatment is reported to preserve renal function and
reduce free radical production, vasoconstrictive throm-
boxane levels, and tubulointerstitial fibrosis, probably
by suppressing the production of superoxide anion,
hydrogen peroxide, malonyldialdehyde, hemeoxygenase
I, and some mediators (TGF-β1 and OPN) [14]. The
preventive effect of rHuEPO on chronic CsA-induced
renal injury is associated with its anti-apoptotic and
anti-inflammatory properties [141]. The exogenous
administration of rosiglitazone, a peroxisome prolifera-
toractivated receptor gamma agonist, has been shown to
reduce chronic CsA-induced renal injury [142,143], but
the mechanism underlying this effect remains unknown.
The blockade of aldosterone receptors with spironolac-
tone has been shown to ameliorate chronic CsA nephropa-
thy [144,145]. Interestingly, spironolactone therapy not
only attenuated structural damage, but also improved
renal function, perhaps via the prevention of TGF-β and
extracellular matrix protein over-expression and the re-
establishment of renal blood flow. 
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To reduce or avoid chronic CsA-induced renal injury,
new immunosuppressive agents and strategies for cal-
cineurin inhibitor minimization, avoidance, or withdrawal
have been emerging in the literature. These new strategies
may ultimately minimize the incidence of nephrotoxicity
and improve allograft and patient survival. Clinical trials
are warranted to investigate the appropriate dosage of
CsA and the effect of eliminating CsA with the addition
of non-nephrotoxic immunosuppressants, such as MMF
and sirolimus, which may permit optimal immunosu-
ppression while avoiding the risk of acute rejection.
However, CsA is still a major immunosuppressant currently
used in both transplant and non-transplant patients.
Considering the increasing rate of late allograft loss or
chronic renal failure associated with chronic CsA nephropa-
thy, a full understanding of the molecular mechanisms
underlying chronic CsA-induced renal injury is essential
to improve long-term outcomes and pharmacological
interventions to delay the progression of chronic CsA
nephropathy.
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